PHILADELPHIA, October 1, 2025 – BlueWhale Bio, Inc., a company dedicated to transforming immune cell therapy manufacturing, today announced that it will present at the 2025 Cell & Gene Meeting on the Mesa Conference taking place October 6-8 in Phoenix, Arizona.
Details of the presentation are as follows:
- Date and time: Wednesday, October 8, 2025, at 10:15 am MST
- Location: FLW Ballroom G at Arizona Biltmore
“At BlueWhale Bio, we’re building a portfolio of essential materials designed set a new benchmark in T-cell activation and to make high-performing cell therapies more accessible—delivered faster, to more patients, and at lower cost,” said Peter Keller, Chief Executive Officer of BlueWhale Bio. “Our Synecta technology platform overcomes key challenges in cell manufacturing by replicating the body’s natural stimulation of immune cells during activation and expansion.”
BlueWhale Bio recently announced dosing of the first patient in a University of Pennyslvania clinical trial using Synecta™ T1 CDNP (cell-derived nanoparticles) to streamline the manufacturing for huCART19-IL18 cells for the treatment of hematologic cancers. At the same time, the company has made its inaugural product, Synecta™ T1 CDNP, available online to academic and industry partners for research use only.
Designed to mimic natural T-cell stimulation, this product composition contains membrane-bound signals, cytokines, and adhesion molecules to enhance T-cell receptor engagement during CAR-T cell manufacturing. In preclinical studies using both healthy donor and patient samples, Synecta T1 outperformed commercially available activation methods by reaching target dose levels faster and with greater consistency across diverse samples—including those derived from exhausted T cells—while generating a higher yield of proliferative CD19 CAR-T cells.
About BlueWhale Bio
BlueWhale Bio is dedicated to accelerating the growth and adoption of cell-based therapies by transforming the manufacturing process of immune cell therapy. The company is developing a portfolio of critical materials that bring the full benefits of higher-performing cell therapies to more patients faster and at lower costs. BlueWhale’s innovations are based on cutting-edge discoveries in cell activation led by Dr. Carl June and Dr. Jim Riley at the University of Pennsylvania. For more information, visit www.bluewhale.bio and follow us on LinkedIn.
###
Media contact:
Cammy Duong
cduong@bluewhale.bio
